Report of the consensus workshop on screening and global strategy for prostate cancer

[1]  I. Thompson,et al.  Disease-specific survival following routine prostate cancer screening by digital rectal examination. , 1993, JAMA.

[2]  J. Oesterling,et al.  Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy. Influence of clinical stage and tumor grade. , 1993, Urology.

[3]  J. Adolfsson,et al.  Deferred treatment in clinically localised prostatic carcinoma. , 1992, British journal of urology.

[4]  B. Têtu,et al.  Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. , 1993, Clinical and investigative medicine. Medecine clinique et experimentale.

[5]  R. Vessella,et al.  The value of serum prostate specific antigen determinations before and after radical prostatectomy. , 1989, The Journal of urology.

[6]  P. Walsh,et al.  Impact of anatomical radical prostatectomy on urinary continence. , 1991, The Journal of urology.

[7]  P. Boyle,et al.  Screening for prostate cancer--necessity or nonsense? , 1993, European journal of cancer.

[8]  W. Catalona,et al.  Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. , 1991, The New England journal of medicine.

[9]  P. Boyle,et al.  Cancer of the prostate: epidemiology and aetiology. , 1987, British journal of urology.

[10]  I. Thompson,et al.  Expectant management of localized prostatic cancer , 1991, Cancer.

[11]  L. Holmberg,et al.  High 10-year survival rate in patients with early, untreated prostatic cancer. , 1992, JAMA.

[12]  E. Messing,et al.  Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  E. Robbins.  Alcman's Partheneion: Legend and Choral Ceremony , 1994, The Classical Quarterly.

[14]  D. Chan,et al.  The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. , 1993, The Journal of urology.

[15]  W. Hepburn,et al.  Randomisation by cluster and the problem of social class bias. , 1989, Journal of epidemiology and community health.

[16]  M. Terris,et al.  Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies. , 1992, The Journal of urology.

[17]  Boris Rubinsky,et al.  Transrectal ultrasound‐guided percutaneous radical cryosurgical ablation of the prostate , 1993, Cancer.

[18]  H. Sandler,et al.  Dose escalation for stage C (T3) prostate cancer: minimal rectal toxicity observed using conformal therapy. , 1992, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  W. Cooner,et al.  Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. , 1990, The Journal of urology.

[20]  J. Oesterling,et al.  Using PSA to eliminate the staging radionuclide bone scan. Significant economic implications. , 1993, The Urologic clinics of North America.

[21]  W. Catalona,et al.  Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. , 1993, JAMA.

[22]  A. Hanlon,et al.  Patterns of Care and RTOG studies in prostate cancer: long-term survival, hazard rate observations, and possibilities of cure. , 1994, International journal of radiation oncology, biology, physics.

[23]  J. Wettlaufer,et al.  Acid phosphatase: its influence on the management of carcinoma of the prostate. , 1984, The Journal of urology.

[24]  R. Hiatt,et al.  Case-control study of screening for prostatic cancer by digital rectal examinations , 1991, The Lancet.

[25]  M. Soloway,et al.  Androgen deprivation prior to radical prostatectomy for T2b and T3 prostate cancer. , 1994, Urology.

[26]  P. Carroll,et al.  Combined role of transrectal ultrasonography, Gleason score, and prostate-specific antigen in predicting organ-confined prostate cancer. , 1993, Urology.

[27]  U. Norming,et al.  Diagnostic methods in the detection of prostate cancer: a study of a randomly selected population of 2,400 men. , 1992, The Journal of urology.

[28]  I. Kaplan,et al.  Prostate cancer. Radiation therapy for localized disease. , 1993, Cancer.

[29]  W. Cooner,et al.  Serum PSA adjusted for volume of transition zone (PSAT) is more accurate than PSA adjusted for total gland volume (PSAD) in detecting adenocarcinoma of the prostate. , 1994, Urology.

[30]  A W Partin,et al.  Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. , 1993, The Urologic clinics of North America.

[31]  J. Goméz,et al.  Serum prostate specific antigen as pre-screening test for prostate cancer. , 1992, The Journal of urology.

[32]  P. Karnauchow.  Screening for prostate cancer. , 1994, Lancet.

[33]  M. Zelen,et al.  Are primary cancer prevention trials feasible? , 1988, Journal of the National Cancer Institute.

[34]  J. Mandel,et al.  Screening in Chronic Disease , 1985 .

[35]  W. Whitmore,et al.  125I Implantation of the Prostate: Dose-Response Considerations , 1978 .

[36]  T. Stamey,et al.  Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate , 1990, Cancer.

[37]  T. Tong,et al.  Cancer statistics, 1991. , 1991, Boletin de la Asociacion Medica de Puerto Rico.

[38]  J. Dekernion,et al.  Prostatic specific antigen related to clinical status 1 to 14 years after radical retropubic prostatectomy. , 1991, British journal of urology.

[39]  D. Siders,et al.  Transrectal ultrasound, digital rectal examination, and prostate-specific antigen: preliminary results of an early detection program for prostate cancer. , 1991, Scandinavian journal of urology and nephrology. Supplementum.

[40]  A. Goodman,et al.  The benefit and cost of prostate cancer early detection , 1993, CA: a cancer journal for clinicians.

[41]  T. Schultheiss,et al.  Factors influencing incidence of acute grade ii morbidity in conformal and standard radiation treatment of prostate cancer: univariate and multivariate analysis , 1993 .

[42]  G E Hanks,et al.  The effect of dose on local control of prostate cancer. , 1988, International journal of radiation oncology, biology, physics.

[43]  R. Abrams,et al.  Phase III trial of hormonal cytoreduction in conjunction with definitive radiotherapy in locally advanced prostate carcinoma: the emerging role of psa in the assessment of outcome , 1993 .

[44]  I M Thompson,et al.  Economics of screening for carcinoma of the prostate. , 1990, The Urologic clinics of North America.

[45]  P Chang,et al.  Hypoechoic lesions of the prostate: clinical relevance of tumor size, digital rectal examination, and prostate specific antigen. , 1990, Radiology.

[46]  M. Benson,et al.  PSA density (PSAD). Role in patient evaluation and management. , 1993, The Urologic clinics of North America.

[47]  T. Tong,et al.  Cancer statistics, 1993 , 1993, CA: a cancer journal for clinicians.

[48]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.

[49]  P Carlsson,et al.  Screening for carcinoma of the prostate by digital rectal examination in a randomly selected population. , 1990, BMJ.

[50]  K. Russell,et al.  Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy. , 1991, The Journal of urology.

[51]  R. Hautmann,et al.  Radical retropubic prostatectomy: morbidity and urinary continence in 418 consecutive cases. , 1994, Urology.

[52]  E. Metter,et al.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. , 1992, JAMA.

[53]  P. Walsh,et al.  A decision analysis of alternative treatment strategies for clinically localized prostate cancer. , 1993, The Journal of urology.